Big Pharma: Early Or Wrong
We recommend overweight in Pharma over a tactical and strategic investment horizon, as challenges, that have recently hampered the industry group’s performance, are dissipating. Likely election outcomes are positive for the industry, while major trends like generative AI applied to drug development and an aging population are long-term tailwinds.
Interested in reading this report?
To access the full BCA Research report, request a complimentary copy
BCA Research | US Equity Strategy
Offers a unique sector and style allocation framework that blends macroeconomic, fundamental, and technical analysis to provide clients with actionable investment recommendations.
Topics
Stay Connected with BCA
Get our latest events and research insights delivered to your inbox.